Latest filing published 17 Jan 2025 for Adaptimmune Therapeutics PLC, €3,148.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
John Lunger, listed as senior executive, appears in our data through filings on Adaptimmune Therapeutics PLC shares, published by SEC (Form 4). Over a trading history stretching from 6 January 2020 to 17 January 2025, the count stands at 27 filings.
The open-market record consists of 27 sales worth €187k, with no purchase. In 2025 alone, the filings show no purchases and 4 sales.
Most recently, on 17 January 2025, the filings show an open-market sale worth €3,148 in Adaptimmune Therapeutics PLC. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations